Before 2013, 92 countries reported extensively drug-resistant Mycobacterium tuberculosis cases to the WHO. Here, we announce the genome sequences of two clinical isolates of extensively drug-resistant tuberculosis (XDR-TB) from Zunyi, China. The genome sequences are composed of 4,411,507 bp and 4,411,515 bp with 2,210 and 2,071 variants, respectively, when compared to the H37Rv genome.

To the Editor—Three years after extensively drug-resistant (XDR) tuberculosis was first described in 2006, Velayati et al [1] drew attention to the emergence of totally drug-resistant (TDR) tuberculosis in a cohort of 15 patients from Iran, resistant to all firstand second-line drugs. Since the first cases of XDR tuberculosis in India were reported from the P. D. Hinduja National Hospital and M...

The article by Andrews et al. demonstrating exogenous reinfection as a cause of multidrug-resistant (MDR) and extensively drug resistant (XDR) tuberculosis (TB) in South Africa in the current issue of the Journal brings chilling news [1]. The authors report that all of the MDR and XDR TB that occurred in patients previously treated for TB was the result of primary transmission, rather than emer...

Treatment outcome in multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) is often unsuccessful, but the particular determinants of poor treatment outcome have remained obscure. The present authors therefore analysed treatment effectiveness and predictors of poor treatment outcome in pulmonary MDR-TB and XDR-TB in Estonia, a European country with one of the highest M...

SETTING Drug-resistant tuberculosis (TB) is an important public health problem in Latvia. OBJECTIVE To document trends, characteristics and treatment outcomes of registered patients with multi-drug-resistant (MDR-) and extensively drug-resistant (XDR-) TB in Latvia from 2000 to 2010. DESIGN A retrospective national cohort study. RESULTS Of 1779 patients, 1646 (92%) had MDR- and 133 (8%) X...

No information is currently available on the influence of injectable second-line drugs on treatment outcomes of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) patients. To investigate this issue, a large series of MDR- and XDR-TB cases diagnosed in Estonia, Germany, Italy and the Russian Federation (Archangels Oblast) between 1999 and 2006 were analysed. All st...

The European Union and European Economic Area (EU/EEA) tuberculosis (TB) surveillance system collects detailed information on resistance to TB drugs. Using this information, we provide an overview of the current TB drug resistance situation and trends in the EU/EEA by performing a descriptive analysis, including analysis of treatment outcomes, of the TB cases reported between January 2007 and D...

Background: India is a high burden country for Tuberculosis (TB). As per the World Health Organization (WHO) statistics, 24000 cases of Multi Drug Resistant (MDR) TB were diagnosed in India in 2014. MDR-TB patients consist of a heterogeneous cohort and management has its challenges. Aims and objectives: We studied the prevalence of PreExtensively Drug Resistant TB (Pre XDR-TB) and Extensively D...

Recently, resistance to additional first-line and injectable drugs was reported to be an independent risk factor for adverse outcomes in multidrug-resistant (MDR) tuberculosis (TB) patients. The aim of the present study was to confirm these observations in MDR-TB patients without HIV infection. MDR-TB patients treated at a tertiary referral hospital in South Korea between January 1996 and Decem...

Background Tuberculosis (TB) caused by Mycobacterium tuberculosis remains a major global health problem. It is the second leading cause of death worldwide. Drug resistance threatens global TB control with the emergence of multidrug resistant (MDR) and extensively drug resistant (XDR) TB. The burden of MDR TB and XDR TB in India is not available as continuous surveillance for drug resistance is ...